<DOC>
	<DOCNO>NCT02034630</DOCNO>
	<brief_summary>To evaluate outcome hematopoietic stem cell transplantation use target busulfan , fludarabine condition regimen genetic rare disease</brief_summary>
	<brief_title>Targeted Busulfan , Fludarabine Conditioning Regimen Hematopoietic Stem Cell Transplantation GRD</brief_title>
	<detailed_description>Busulfan highly toxic drug narrow therapeutic window use condition hematopoietic stem cell transplantation . High exposure associate systemic toxicity veno-occlusive disease ( VOD ) underexposure associate graft failure relapse . In study investigator plan improve outcome hematopoietic stem cell transplantation use optimal busulfan dose pharmacokinetic study .</detailed_description>
	<mesh_term>Rare Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Patients diagnose genetic rare disease . 2 . Patients need hematopoietic stem cell transplantation 3 . Age : 21 year 4 . Performance status : ECOG 02 . 5 . Patients must free significant functional deficit major organ , follow eligibility criterion may modify individual case . 1 . Heart : shortening fraction &gt; 30 % ejection fraction &gt; 45 % . 2 . Liver : total bilirubin &lt; 2 × upper limit normal ; ALT &lt; 3 × upper limit normal . 3 . Kidney : creatinine &lt; 2 × normal creatinine clearance ( GFR ) &gt; 60 ml/min/1.73m2 . 6 . Patients must lack active viral infection active fungal infection . 7 . Appropriate donor available : Matched 6/6 A , B , DR locus . 8 . Patients ( one parent patient age &lt; 19 ) sign inform consent . 1 . Pregnant nursing woman . 2 . Malignant nonmalignant illness uncontrolled whose control may jeopardize complication study therapy . 3 . Psychiatric disorder would preclude compliance .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>hematopoietic stem cell transplantation</keyword>
</DOC>